KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Raw Materials (2018 - 2020)

Historic Raw Materials for Amneal Pharmaceuticals (AMRX) over the last 3 years, with Q1 2020 value amounting to $162.7 million.

  • Amneal Pharmaceuticals' Raw Materials changed N/A to $162.7 million in Q1 2020 from the same period last year, while for Mar 2020 it was $162.7 million, marking a year-over-year change of. This contributed to the annual value of $172.2 million for FY2019, which is 522.7% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Raw Materials stood at $162.7 million for Q1 2020.
  • Amneal Pharmaceuticals' Raw Materials' 5-year high stood at $182.8 million during Q3 2019, with a 5-year trough of $162.7 million in Q1 2020.
  • For the 3-year period, Amneal Pharmaceuticals' Raw Materials averaged around $174.8 million, with its median value being $176.9 million (2018).
  • Over the last 5 years, Amneal Pharmaceuticals' Raw Materials had its largest YoY gain of 522.7% in 2019, and its largest YoY loss of 522.7% in 2019.
  • Amneal Pharmaceuticals' Raw Materials (Quarter) stood at $181.7 million in 2018, then fell by 5.23% to $172.2 million in 2019, then fell by 5.48% to $162.7 million in 2020.
  • Its Raw Materials stands at $162.7 million for Q1 2020, versus $172.2 million for Q4 2019 and $182.8 million for Q3 2019.